samedan logo
 
 
spacer
home > pmps > spring 2004 > dynamic modelling and simulation for nasal drug delivery
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Dynamic Modelling and Simulation for Nasal Drug Delivery

Nasal drug delivery is rapidly emerging as a route for drug administration. Computer aided engineering simulation tools, such as computational fluid dynamics (CFD), are extensively used across a wide range of industry sectors and this same technology is now being used for the simulation of nasal air flow passages and the deposition of drug particles. This article presents a study in which CFD simulation technology was applied. For the study, air flow velocities and distribution profiles of the drug particles were mapped as they travelled through the nasal cavity geometry chosen for analysis. The study also looked at the effects of key drug system formulation variables, such as particle size and densities, on drug deposition. The results show that simulations can be effectively used for the optimisation of nasal drug delivery systems, thereby minimising experimental work and clinical trials.

Nasal drug delivery systems are rapidly developing as a method of drug administration and are emerging as an alternative to oral and injection routes of delivery (1,2). Some of the key advantages of using the nasal administration route are the improved speed of the pharmacological action as a feature of improved accessibility to the vasculature, and the ability to achieve target-specific drug delivery.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Jin Yan, Dr Atul Karanjkar and Martin Branagan, Healthcare Team at Fluent Europe Ltd

Dr Jin Yan is a Senior CFD Analyst at Fluent Europe Ltd working in Technical Services. He has a PhD in Thermodynamics from Durham University and has spent a total of five years at Fluent Europe working in both software and consultancy.

Dr Atul Karanjkar is Business Development Manager for Fluent Europe's Healthcare team. He has extensive experience within the health care industry in both Europe and North America. Dr Karanjkar has a PhD in Chemical Engineering and an MBA in Strategic Management.

Martin Branagan is Account Manager for Fluent Europe's Healthcare Team. He has over 12 years of health care industry experience through working at Smith & Nephew, where he was a Research Scientist, Project Manager and finally a Safety Consultant for the worldwide operations of the company, prior to joining Fluent.
spacer
Dr Jin Yan
spacer
spacer
spacer
Dr Atul Karanjkar
spacer
spacer
spacer
Martin Branagan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Myonex Opens New Global Headquarters

Myonex, a leading global clinical trial supply company, marked the opening of its new global headquarters and US operational facility with a ribbon-cutting ceremony on the company’s 14-acre campus.
More info >>

White Papers

Life Cycle of an Analytical Method - a Case Study on the Monocyte Activation Test

Wickham Laboratories Limited

Pyrogens, a heterogeneous group of fever inducing contaminants, are comprised of microbial and non-microbial compounds; e.g. endotoxin (lipopolysaccharide, LPS) produced by Gram-negative bacteria, lipoteichoic acid (LTA) from Gram-positive bacteria, bacterial DNA (CpG-motive), endogenous pyrogens, virus and fungi particles or even fragments of packaging materials, plastic and dust. Contaminat ion wi th pyrogens in pharmaceutical products, biotherapeutics and on medical devices can lead to life threatening fever reactions. To ensure consumer safety, pyrogen testing is mandatory for parenteral products and medical devices.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement